These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 8968365)
1. Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function. Tachibana I; Kanagawa K; Yamamoto Y; Otsuki M J Pharmacol Exp Ther; 1996 Dec; 279(3):1404-12. PubMed ID: 8968365 [TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. Lotti VJ; Pendleton RG; Gould RJ; Hanson HM; Chang RS; Clineschmidt BV J Pharmacol Exp Ther; 1987 Apr; 241(1):103-9. PubMed ID: 2437282 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754 [TBL] [Abstract][Full Text] [Related]
4. Roles of endogenous cholecystokinin in biliary, pancreatic and gastric function: studies with L-364,718, a specific cholecystokinin receptor antagonist. Pendleton RG; Bendesky RJ; Schaffer L; Nolan TE; Gould RJ; Clineschmidt BV J Pharmacol Exp Ther; 1987 Apr; 241(1):110-6. PubMed ID: 2437283 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide. Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389 [TBL] [Abstract][Full Text] [Related]
6. Different actions of CCK on pancreatic and gastric growth in the rat: effect of CCK(A) receptor blockade. Varga G; Kisfalvi K; Pelosini I; D'Amato M; Scarpignato C Br J Pharmacol; 1998 Jun; 124(3):435-40. PubMed ID: 9647465 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of gastric emptying is a physiological action of cholecystokinin. Debas HT; Farooq O; Grossman MI Gastroenterology; 1975 May; 68(5 Pt 1):1211-7. PubMed ID: 1126597 [TBL] [Abstract][Full Text] [Related]
8. Disruption of cholecystokinin (CCK)-B receptor gene did not modify bile or pancreatic secretion or pancreatic growth: a study in CCK-B receptor gene knockout mice. Miyasaka K; Shinozaki H; Suzuki S; Sato Y; Kanai S; Masuda M; Jimi A; Nagata A; Matsui T; Noda T; Kono A; Funakoshi A Pancreas; 1999 Aug; 19(2):114-8. PubMed ID: 10438156 [TBL] [Abstract][Full Text] [Related]
9. Effects of a new benzodiazepine derivative cholecystokinin receptor antagonist FK480 on pancreatic exocrine secretion in anesthetized rats. Tachibana I; Otsuki M Dig Dis Sci; 1994 Jun; 39(6):1321-8. PubMed ID: 8200267 [TBL] [Abstract][Full Text] [Related]
10. The effects of antagonists of receptors for gastrin, cholecystokinin and bombesin on growth of gastroduodenal mucosa and pancreas. Dembiński A; Warzecha Z; Konturek SJ; Cai RZ; Schally AV J Physiol Pharmacol; 1991 Jun; 42(2):195-209. PubMed ID: 1664265 [TBL] [Abstract][Full Text] [Related]
11. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs. Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032 [TBL] [Abstract][Full Text] [Related]
12. Opposing central and peripheral actions of brain-gut peptides: a basis for regulation of gastric function. Pappas TN; Taché Y; Debas HT Surgery; 1985 Aug; 98(2):183-90. PubMed ID: 2862711 [TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin stimulates ascorbic acid secretion through its specific receptor in the perfused stomach of rats. Muto N; Eguchi R; Akagi Y; Itoh N; Tanaka K Res Commun Mol Pathol Pharmacol; 1998 Aug; 101(2):127-36. PubMed ID: 9821209 [TBL] [Abstract][Full Text] [Related]
14. Effect of cadmium and bombesin on exocrine pancreatic secretions and plasma levels of gastrin and cholecystokinin (CCK) in rats. Chowdhury P; Ami M; Rayford PL Ann Clin Lab Sci; 1986; 16(6):479-87. PubMed ID: 3800302 [TBL] [Abstract][Full Text] [Related]
15. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851 [TBL] [Abstract][Full Text] [Related]
16. Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man. Hildebrand P; Beglinger C; Gyr K; Jansen JB; Rovati LC; Zuercher M; Lamers CB; Setnikar I; Stalder GA J Clin Invest; 1990 Mar; 85(3):640-6. PubMed ID: 2312719 [TBL] [Abstract][Full Text] [Related]
17. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Scarpignato C; Kisfalvi I; D'Amato M; Varga G Aliment Pharmacol Ther; 1996 Jun; 10(3):411-9. PubMed ID: 8791971 [TBL] [Abstract][Full Text] [Related]
18. Effect of a novel cholecystokinin receptor antagonist, FK480, administered intraduodenally, on pancreatic secretion in rats. Moriyoshi Y; Shiratori K; Takeuchi T; Watanabe S Pancreas; 1995 Apr; 10(3):295-300. PubMed ID: 7542771 [TBL] [Abstract][Full Text] [Related]
19. Effect of deramciclane, a new 5-HT receptor antagonist, on cholecystokinin-induced changes in rat gastrointestinal function. Varga G; Kordás K; Burghardt B; Gacsályi I; Szénási G Eur J Pharmacol; 1999 Feb; 367(2-3):315-23. PubMed ID: 10079007 [TBL] [Abstract][Full Text] [Related]
20. Supramaximal CCK-58 does not induce pancreatitis in the rat: role of pancreatic water secretion. Yamamoto M; Reeve JR; Green GM Am J Physiol Gastrointest Liver Physiol; 2007 Apr; 292(4):G964-74. PubMed ID: 17158258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]